How India Exports Oxaliplatin to the World

In the United States, oxaliplatin was initially approved by the FDA in August 2002 under the brand name Eloxatin. Generic versions received approval starting in August 2009. However, patent disputes led to a temporary halt in generic production in 2010, which resumed in 2012. As of February 2026, all original Eloxatin formulations have been discontinued. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for oxaliplatin, indicating a competitive generic market. Notably, the United States accounted for 9.4% of India's oxaliplatin exports between 2022 and 2026, underscoring the significance of the U.S. market for Indian exporters.

Oxaliplatin received European approval in 1996. The European Medicines Agency (EMA) continues to monitor its safety and efficacy. For instance, in February 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorization for Columvi, a medicinal product that includes oxaliplatin in combination with gemcitabine for treating certain types of lymphoma. This reflects ongoing regulatory oversight and adaptation to emerging clinical data. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers exporting to the EU and UK, ensuring product quality and safety.

Oxaliplatin is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its importance in cancer treatment. It is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters across different regions.

In India, oxaliplatin is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for exporting pharmaceuticals, ensuring compliance with national regulations.

The primary patents for oxaliplatin have expired, with the last significant patent (US Patent No. 5,420,319) expiring on August 8, 2016. This has led to increased generic competition globally, including from Indian manufacturers.

In February 2025, the EMA's CHMP adopted a positive opinion recommending a change to the marketing authorization for Columvi, a medicinal product that includes oxaliplatin in combination with gemcitabine for treating certain types of lymphoma. This reflects ongoing regulatory oversight and adaptation to emerging clinical data.

In September 2022, a patent (CN111205332A) was filed describing the development of oxaliplatin co-crystals using flavonoids to improve solubility and stability in the gastrointestinal tract, potentially reducing side effects. This innovation could influence future formulations and therapeutic applications.

These developments underscore the dynamic nature of the regulatory and industrial landscape surrounding oxaliplatin, with implications for manufacturers, exporters, and healthcare providers.

India's pharmaceutical industry, including the production of Oxaliplatin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. This dependency exposes the supply chain to vulnerabilities stemming from geopolitical tensions and regulatory changes. For instance, in June 2025, environmental regulations in China led to the shutdown of several chemical manufacturing plants, causing significant disruptions in the supply of KSMs to Indian API manufacturers. Such events underscore the fragility of the supply chain due to over-reliance on a single source for critical raw materials.

The COVID-19 pandemic further highlighted these vulnerabilities. During the early months of 2020, lockdowns and transportation restrictions in China resulted in delays and shortages of essential KSMs, impacting the production timelines of Indian pharmaceutical companies. These incidents emphasize the need for diversification in sourcing strategies to mitigate risks associated with supply chain disruptions.

Our proprietary trade data indicates that the top five exporters of Oxaliplatin from India account for 66.1% of the total export value, with FRESENIUS KABI ONCOLOGY LIMITED alone contributing 35.7%. This high level of supplier concentration poses a significant risk, as any operational or financial issues within these key companies could disrupt the entire supply chain.

To address such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in July 2020, aiming to boost domestic manufacturing of APIs and reduce dependency on imports. While this initiative has led to increased investment in local API production, the transition period means that the supply chain remains vulnerable in the short term.

Recent geopolitical events have further exacerbated supply chain vulnerabilities. In February 2026, the closure of the Strait of Hormuz due to military conflicts led to significant disruptions in global shipping routes. This chokepoint is crucial for the transportation of crude oil and petrochemical products, essential for pharmaceutical manufacturing. The closure resulted in increased transportation costs and delays, impacting the timely delivery of raw materials and finished products.

Additionally, tensions in the Red Sea region have led to rerouting of shipping lanes, causing further delays and increased costs. The FDA has acknowledged these challenges, emphasizing the need for robust supply chain monitoring and proactive measures to prevent drug shortages.

To enhance the resilience of the Oxaliplatin supply chain, the following actionable steps are recommended:

• Diversify API and KSM Sources: Develop relationships with alternative suppliers in different geographic regions to reduce dependency on a single country.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI scheme to boost local production of critical APIs and KSMs.

• Enhance Supplier Due Diligence: Conduct regular assessments of key suppliers to identify potential risks and develop contingency plans.

• Monitor Geopolitical Developments: Establish a dedicated team to track global events that could impact supply chains and develop proactive response strategies.

• Invest in Supply Chain Technologies: Implement advanced tracking and analytics tools to gain real-time visibility into the supply chain and quickly address disruptions.

RISK_LEVEL: HIGH

Given the current geopolitical climate, high supplier concentration, and dependency on imported raw materials, the supply chain risk for Oxaliplatin exported from India is assessed as high. Immediate and strategic actions are necessary to mitigate these risks and ensure supply chain continuity.